Expert Interviews

An overview of recent data on selinexor, carfilzomib, and dexamethasone in triple-class refractory multiple myeloma, and treatment options to replace belantamab.

Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.

Shared insight on possible real-world applications for FcRH5-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.

Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.

Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.

Trial results presented at a recent medical conference demonstrated that the use of shorter duration radiation is safe and effective in prostate cancer, as well as a type of rare cancer, according to an expert.

A brief review of Trop-2 directed therapy and its role in the HR+ metastatic breast cancer treatment landscape.

Centering discussion on HER2-targeted trastuzumab deruxtecan, experts reflect on the presence of HER2-low metastatic breast cancer and optimal treatment strategies.

Data presented at a recent medical conference shows that there is continued interest in observing the effects of fewer radiation treatments across several cancer types, according to an expert.

Experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.

Before closing out their discussion on renal cell carcinoma, key opinion leaders highlight efforts to optimize the management of non–clear cell disease with immunotherapy.

Hun Ju Lee, MD, reviews results from part C of the phase 2 SGN35-27 trial for patients with early-stage classical Hodgkin lymphoma treated with brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine.

An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.

An expert from The University of Texas, MD Anderson Cancer Center says that a brentuximab vedotin–based combination was well-tolerated in patients with advanced-stage Hodgkin lymphoma, according to results presented at 2022 ASH.

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.

Catherine Coombs, MD, reviews data on BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in the first-line treatment of CLL, and how she approaches selecting the appropriate BTK inhibitor in practice.

The panel closes their discussion by musing on the future of HER2 mBC treatments.

An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.

Virginia Kaklamani, MD and Heather McArthur, MD, MPH close by sharing exciting prospects in metastatic breast cancer treatment.